Hubei Xianglian Pharmaceutical

Hubei Xianglian Pharmaceutical is a Chinese pharmaceutical company headquartered in Ezhou, Hubei, specializing in the research, development, and industrialization of cardiovascular medicines. The company is best known for the commercialization of Guanfu Base Hydrochloride (Acehytisine Hydrochloride), a Class 1.1 innovative anti-arrhythmic drug approved in China for the treatment of paroxysmal supraventricular tachycardia. Hubei Xianglian operates advanced manufacturing facilities that are GMP-certified for both active pharmaceutical ingredients (APIs) and finished dosage forms. The company's business model focuses on integrating scientific research from academic institutions with large-scale industrial production. It maintains a strong presence in the Hubei regional biotech corridor and targets the domestic Chinese market for specialized cardiovascular care. Beyond its flagship innovative drug, the company also engages in the production of high-quality generic chemical drugs.